Highlights LadRx Corporation

Equities

LADX

US2328287071

Market Closed - OTC Markets Other stock markets 12:49:16 10/05/2024 am IST			5-day change	1st Jan Change
2.76 ^USD	-8.00%		-11.54%	+112.31%

27/03	LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/01	Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	12/01	DJ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Reverse Split: 1 of 100	17/23/17	FA
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
LadRx Corporation has filed an IPO in the amount of $24 million.	14/23/14	CI
LadRx Highlights Patent Issued for Its LADR Technology	27/23/27	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Investor Presentation: November 2022	17/22/17	PU
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Investor Presentation: September 2022	27/22/27	PU
Investor Presentation: August 2022	11/22/11	PU
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/22/11	CI
Investor Presentation: July 2022	15/22/15	PU
CytRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI
CytRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	23/22/23	CI
CytRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
CytRx Corporation Highlights ImmunityBio, Inc.'s Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment	14/21/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LadRx Corporation

Equities

LADX

US2328287071

Highlights

Filters